View Future GrowthNeuphoria Therapeutics 과거 순이익 실적과거 기준 점검 0/6Neuphoria Therapeutics은 연평균 7%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 36.2%의 비율로 증가했습니다. 매출은 연평균 49.9%의 비율로 증가했습니다.핵심 정보6.97%순이익 성장률-45.09%주당순이익(EPS) 성장률Biotechs 산업 성장률17.04%매출 성장률49.93%자기자본이익률-59.24%순이익률131,387.14%최근 순이익 업데이트31 Mar 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates분석 기사 • Jun 04Here's Why We're A Bit Worried About Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...분석 기사 • Feb 19Neuphoria Therapeutics (NASDAQ:NEUP) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...공시 • Jan 08+ 1 more updateNeuphoria Therapeutics Inc. Announces Executive Changes Effective January 1, 2026Neuphoria Therapeutics Inc. terminated Spyridon "Spyros" Papapetropoulos' employment as President and Chief Executive Officer effective December 31, 2025, and Mr. Papapetropoulos will remain as a member of the Company's Board of Directors. Effective January 1, 2026, Mr. Papapetropoulos entered into a Consulting Agreement with the Company under which he will serve as interim CEO for up to twelve months to support the execution of the Company's contemplated strategic transaction and ensure a seamless transition. All post-termination obligations of Independent Contractor under the Prior Employment Agreement, including the Proprietary Information and Inventions Agreement executed in conjunction with the Prior Employment Agreement, and including without limitation provisions relating to confidentiality, non-disclosure, protection of trade secrets, intellectual property, non-disparagement, cooperation, and return of Company property, shall continue in full force and effect and are hereby incorporated by reference.공시 • Dec 03+ 1 more updateLynx1 Master Sends a Letter to the Shareholders of Neuphoria TherapeuticsOn December 2, 2025, Lynx1 Master Fund LP sent an open letter to the shareholders of Neuphoria Therapeutics Inc., detailing why it is calling for change at the Company. In the letter, Lynx1 noted that the Company's board of directors has demonstrated a pattern of mismanagement that has led to clinical failures and an opaque review of strategic alternatives. Lynx1 resubmitted its offer to acquire all of the outstanding shares of the Company for $4.75 per share in cash, preserving the economics of its initial offer which was withdrawn due to the Board's intervening actions. Lynx1 also noted it has nominated two highly qualified, independent director candidates, Dr. Stephen Doberstein and Kimberly Smith, for election to the Board at the Company's 2025 annual meeting of shareholders. Lynx1 urged shareholders to vote FOR its independent nominees on the BLUE universal proxy card to restore accountability and maximize value amid the Company's ongoing strategic review.분석 기사 • Nov 05Does This Valuation Of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Imply Investors Are Overpaying?Key Insights Neuphoria Therapeutics' estimated fair value is US$3.35 based on 2 Stage Free Cash Flow to Equity...공시 • Oct 31Neuphoria Therapeutics Inc., Annual General Meeting, Dec 09, 2025Neuphoria Therapeutics Inc., Annual General Meeting, Dec 09, 2025.공시 • Oct 21Neuphoria Therapeutics Provides Update on Affirm-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety DisorderNeuphoria Therapeutics Inc. announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder (SAD) did not meet its primary endpoint of change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. In addition, analyses of secondary endpoints did not demonstrate statistically significant differences. The Company expects its current cash position to be sufficient to fund operations through the second fiscal quarter of 2027. The AFFIRM-1 phase 3 clinical trial was a multi-center, double-blind, two-arm, parallel group, placebo-controlled trial evaluating the safety and efficacy of a single, acute dose of 225 mg of BNC210 versus placebo. Participants in the trial were randomized 1:1 to receive a single dose of 225 mg BNC210 or matched placebo. The primary endpoint of the trial was the change from baseline to the average the performance phase of the public speak challenge in Subjective Units of distress Scale (SUDS) score. Secondary endpoints included change in SUDS score from baseline to the average of The anticipation phase, changes in the Clinical Global Impression - Severity (CGI-S) scale, self-assessment with the State Trait Anxiety Inventory (STAI-State) and the Patient Global Impression - Improvement (PGI-I) scale. A follow-up visit occurred one week after the public speaking challenge.공시 • Sep 17Nasdaq Grants Neuphoria Therapeutics Inc. an Extension of 180 Calendar Days to Regain Compliance with the Listing RuleAs previously disclosed on July 18, 2025, Neuphoria Therapeutics Inc. (the Company") received a deficiency notification letter (the Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the Listing Rule") as a result of the Company's failure to hold an annual general meeting of stockholders within twelve months of the end of the Company's fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company's fiscal year end. Pursuant to and in response to that Notice, the Company timely submitted its plan to Nasdaq to regain compliance with the Listing Rule (the Plan"). In response to the Company's Plan, on September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension of 180 calendar days (the Compliance Period") from the end of the Company's fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. To this end, the Company intends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy statement and notice of shareholder meeting related to the Company's 2025 annual general shareholder meeting, and further intends to hold such annual shareholder meeting within the Compliance Period.공시 • Sep 04Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)Neuphoria Therapeutics Inc. announced the achievement of target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial evaluating lead candidate BNC-210 as a first-in-class, acute, "as needed", fast-acting treatment for social anxiety disorder (SAD). BNC-210 is an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder (PTSD). BNC-210 has been given FDA Fast Track designation for acute treatment of SAD and other anxiety related disorders, and for treatment of PTSD and other trauma and stressor related disorders. BNC-210 has demonstrated rapid-onset, broad and meaningful anti-an anxiety effects in completed clinical trials in SAD, generalized anxiety disorder (GAD) and panic attacks without evidence of sedation, impairments in cognition or addiction potential. The AFFIRM-1 phase 3 clinical trial is a multi-center, double-blind, two-arm, parallel group, placebo-controlled trial evaluating the safety and efficacy of a single, acute dose of 225 mg of BNC-210 versus placebo. Participants in the trial are randomized 1:1 to receive a single dose of 225 mg BNC-210 or matched placebo. The primary endpoint of the trial is the change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. Secondary endpoints include change in SUDS score from baseline to the average of The Clinical Global Impression - Severity (CGI-S) scale, and self-assessment with the State Trait Anxiety Inventory (STAI-State) and the Patient Global Impression - Improvement (PGI-I) scale. A follow-up visit occurs one week after the public speaking challenge. SAD can interfere with a person's ability to work, make it difficult to maintain relationships, family relationships, and romantic partnerships, cause a person to avoid lifestyle activities like dining out and traveling, and make normal parts of everyday life such as grocery shopping, calling a handyman, or picking up coffee challenging.공시 • Jul 30Neuphoria Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $6.337229 million.Neuphoria Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $6.337229 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Jul 21Neuphoria Therapeutics Receives a Deficiency Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn July 18, 2025, Neuphoria Therapeutics Inc. received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the “Listing Rule”) as a result of the Company’s failure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company’s fiscal year end. The Company notes that it has held a shareholder meeting every year for the past number of years on or about November or December of each such year, including the extensive shareholder meeting we held in relation to our redomicilation and scheme of arrangement to become a Delaware corporation in December 2024. To this end, the Company had already planned to hold its 2025 annual general shareholder meeting on or about November 2025, in-line with past annual shareholder meeting dates, in satisfaction of the compliance item provided in the Notice and which will be consistent with the Plan (defined below) that the Company intends to submit on a timely basis. The Company also looks forward to timely filing its annual report on or before September 30, 2025, as well as its upcoming annual shareholder meeting communication(s) shortly thereafter. The Company has until September 1, 2025 to submit a plan to regain compliance with the Listing Rule (the “Plan”). Pursuant to the Notice, if Nasdaq accepts the Plan, Nasdaq has the discretion to grant the Company an exception of up to 180 calendar days (the “Compliance Period”) from the end of the Company’s fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq.공시 • May 16Neuphoria Therapeutics Inc. announced delayed 10-Q filingOn 05/15/2025, Neuphoria Therapeutics Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 20Bionomics Limited has filed a Follow-on Equity Offering in the amount of $2 million.Bionomics Limited has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Transaction Features: At the Market Offering매출 및 비용 세부 내역Neuphoria Therapeutics가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqGM:NEUP 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 260-178731 Dec 2515-67930 Sep 2516-981130 Jun 251608931 Mar 251668831 Dec 241-881330 Sep 240-1181130 Jun 240-158931 Mar 240-1891331 Dec 230-20111330 Sep 230-22101330 Jun 230-2191331 Mar 232-197631 Dec 224-175030 Sep 224-155030 Jun 224-155031 Mar 222-166031 Dec 210-166030 Sep 211-115030 Jun 211-74031 Mar 211-34031 Dec 20114030 Sep 202-24030 Jun 202-43031 Dec 194-34030 Sep 195-54030 Jun 195-76031 Mar 196-148031 Dec 185-208030 Sep 187-198030 Jun 189-198031 Mar 1815-127031 Dec 1721-56030 Sep 1721-56030 Jun 1721-56031 Mar 1717-98031 Dec 1612-129030 Sep 1614-139030 Jun 1614-128031 Mar 1614-148031 Dec 1513-157030 Sep 1512-136030 Jun 1512-1370양질의 수익: NEUP 은(는) 현재 수익성이 없습니다.이익 마진 증가: NEUP는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: NEUP는 수익성이 없지만 지난 5년 동안 연평균 7%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 NEUP의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: NEUP은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(54.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: NEUP는 현재 수익성이 없으므로 자본 수익률이 음수(-59.24%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/08 19:44종가2026/06/08 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Neuphoria Therapeutics Inc.는 5명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tanushree JainBell PotterEsther Lannie HongBerenbergKatherine GenisEdison Investment Research2명의 분석가 더 보기
분석 기사 • Jun 04Here's Why We're A Bit Worried About Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationJust because a business does not make any money, does not mean that the stock will go down. For example, although...
분석 기사 • Feb 19Neuphoria Therapeutics (NASDAQ:NEUP) Is In A Strong Position To Grow Its BusinessJust because a business does not make any money, does not mean that the stock will go down. For example, although...
공시 • Jan 08+ 1 more updateNeuphoria Therapeutics Inc. Announces Executive Changes Effective January 1, 2026Neuphoria Therapeutics Inc. terminated Spyridon "Spyros" Papapetropoulos' employment as President and Chief Executive Officer effective December 31, 2025, and Mr. Papapetropoulos will remain as a member of the Company's Board of Directors. Effective January 1, 2026, Mr. Papapetropoulos entered into a Consulting Agreement with the Company under which he will serve as interim CEO for up to twelve months to support the execution of the Company's contemplated strategic transaction and ensure a seamless transition. All post-termination obligations of Independent Contractor under the Prior Employment Agreement, including the Proprietary Information and Inventions Agreement executed in conjunction with the Prior Employment Agreement, and including without limitation provisions relating to confidentiality, non-disclosure, protection of trade secrets, intellectual property, non-disparagement, cooperation, and return of Company property, shall continue in full force and effect and are hereby incorporated by reference.
공시 • Dec 03+ 1 more updateLynx1 Master Sends a Letter to the Shareholders of Neuphoria TherapeuticsOn December 2, 2025, Lynx1 Master Fund LP sent an open letter to the shareholders of Neuphoria Therapeutics Inc., detailing why it is calling for change at the Company. In the letter, Lynx1 noted that the Company's board of directors has demonstrated a pattern of mismanagement that has led to clinical failures and an opaque review of strategic alternatives. Lynx1 resubmitted its offer to acquire all of the outstanding shares of the Company for $4.75 per share in cash, preserving the economics of its initial offer which was withdrawn due to the Board's intervening actions. Lynx1 also noted it has nominated two highly qualified, independent director candidates, Dr. Stephen Doberstein and Kimberly Smith, for election to the Board at the Company's 2025 annual meeting of shareholders. Lynx1 urged shareholders to vote FOR its independent nominees on the BLUE universal proxy card to restore accountability and maximize value amid the Company's ongoing strategic review.
분석 기사 • Nov 05Does This Valuation Of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Imply Investors Are Overpaying?Key Insights Neuphoria Therapeutics' estimated fair value is US$3.35 based on 2 Stage Free Cash Flow to Equity...
공시 • Oct 31Neuphoria Therapeutics Inc., Annual General Meeting, Dec 09, 2025Neuphoria Therapeutics Inc., Annual General Meeting, Dec 09, 2025.
공시 • Oct 21Neuphoria Therapeutics Provides Update on Affirm-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety DisorderNeuphoria Therapeutics Inc. announced that the AFFIRM-1 Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder (SAD) did not meet its primary endpoint of change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. In addition, analyses of secondary endpoints did not demonstrate statistically significant differences. The Company expects its current cash position to be sufficient to fund operations through the second fiscal quarter of 2027. The AFFIRM-1 phase 3 clinical trial was a multi-center, double-blind, two-arm, parallel group, placebo-controlled trial evaluating the safety and efficacy of a single, acute dose of 225 mg of BNC210 versus placebo. Participants in the trial were randomized 1:1 to receive a single dose of 225 mg BNC210 or matched placebo. The primary endpoint of the trial was the change from baseline to the average the performance phase of the public speak challenge in Subjective Units of distress Scale (SUDS) score. Secondary endpoints included change in SUDS score from baseline to the average of The anticipation phase, changes in the Clinical Global Impression - Severity (CGI-S) scale, self-assessment with the State Trait Anxiety Inventory (STAI-State) and the Patient Global Impression - Improvement (PGI-I) scale. A follow-up visit occurred one week after the public speaking challenge.
공시 • Sep 17Nasdaq Grants Neuphoria Therapeutics Inc. an Extension of 180 Calendar Days to Regain Compliance with the Listing RuleAs previously disclosed on July 18, 2025, Neuphoria Therapeutics Inc. (the Company") received a deficiency notification letter (the Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (Nasdaq"). The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the Listing Rule") as a result of the Company's failure to hold an annual general meeting of stockholders within twelve months of the end of the Company's fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company's fiscal year end. Pursuant to and in response to that Notice, the Company timely submitted its plan to Nasdaq to regain compliance with the Listing Rule (the Plan"). In response to the Company's Plan, on September 10, 2025, Nasdaq provided the Company further notice that is has accepted our Plan and granted the Company an extension of 180 calendar days (the Compliance Period") from the end of the Company's fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. To this end, the Company intends to file its annual report on Form 10-K on or before September 29, 2025, and thereafter, the Company intends to timely file a proxy statement and notice of shareholder meeting related to the Company's 2025 annual general shareholder meeting, and further intends to hold such annual shareholder meeting within the Compliance Period.
공시 • Sep 04Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)Neuphoria Therapeutics Inc. announced the achievement of target enrollment of 332 participants in the AFFIRM-1 Phase 3 trial evaluating lead candidate BNC-210 as a first-in-class, acute, "as needed", fast-acting treatment for social anxiety disorder (SAD). BNC-210 is an oral, proprietary, selective negative allosteric modulator of the a7 nicotinic acetylcholine receptor under development for the treatment of SAD and post-traumatic stress disorder (PTSD). BNC-210 has been given FDA Fast Track designation for acute treatment of SAD and other anxiety related disorders, and for treatment of PTSD and other trauma and stressor related disorders. BNC-210 has demonstrated rapid-onset, broad and meaningful anti-an anxiety effects in completed clinical trials in SAD, generalized anxiety disorder (GAD) and panic attacks without evidence of sedation, impairments in cognition or addiction potential. The AFFIRM-1 phase 3 clinical trial is a multi-center, double-blind, two-arm, parallel group, placebo-controlled trial evaluating the safety and efficacy of a single, acute dose of 225 mg of BNC-210 versus placebo. Participants in the trial are randomized 1:1 to receive a single dose of 225 mg BNC-210 or matched placebo. The primary endpoint of the trial is the change from baseline to the average of the performance phase of the public speaking challenge in Subjective Units of Distress Scale (SUDS) scores. Secondary endpoints include change in SUDS score from baseline to the average of The Clinical Global Impression - Severity (CGI-S) scale, and self-assessment with the State Trait Anxiety Inventory (STAI-State) and the Patient Global Impression - Improvement (PGI-I) scale. A follow-up visit occurs one week after the public speaking challenge. SAD can interfere with a person's ability to work, make it difficult to maintain relationships, family relationships, and romantic partnerships, cause a person to avoid lifestyle activities like dining out and traveling, and make normal parts of everyday life such as grocery shopping, calling a handyman, or picking up coffee challenging.
공시 • Jul 30Neuphoria Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $6.337229 million.Neuphoria Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $6.337229 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Jul 21Neuphoria Therapeutics Receives a Deficiency Notification Letter from the Listing Qualifications Staff of the Nasdaq Stock MarketOn July 18, 2025, Neuphoria Therapeutics Inc. received a deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. The Notice indicated that the Company was not in compliance with Nasdaq Listing Rule 5620(a) (the “Listing Rule”) as a result of the Company’s failure to hold an annual meeting of stockholders within twelve months of the end of the Company’s fiscal year ended June 30, 2024. The Listing Rule requires that a Nasdaq-listed company hold an annual meeting of shareholders no later than one year after the end of the company’s fiscal year end. The Company notes that it has held a shareholder meeting every year for the past number of years on or about November or December of each such year, including the extensive shareholder meeting we held in relation to our redomicilation and scheme of arrangement to become a Delaware corporation in December 2024. To this end, the Company had already planned to hold its 2025 annual general shareholder meeting on or about November 2025, in-line with past annual shareholder meeting dates, in satisfaction of the compliance item provided in the Notice and which will be consistent with the Plan (defined below) that the Company intends to submit on a timely basis. The Company also looks forward to timely filing its annual report on or before September 30, 2025, as well as its upcoming annual shareholder meeting communication(s) shortly thereafter. The Company has until September 1, 2025 to submit a plan to regain compliance with the Listing Rule (the “Plan”). Pursuant to the Notice, if Nasdaq accepts the Plan, Nasdaq has the discretion to grant the Company an exception of up to 180 calendar days (the “Compliance Period”) from the end of the Company’s fiscal year, or until December 29, 2025, to regain compliance with the Listing Rule. The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq.
공시 • May 16Neuphoria Therapeutics Inc. announced delayed 10-Q filingOn 05/15/2025, Neuphoria Therapeutics Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 20Bionomics Limited has filed a Follow-on Equity Offering in the amount of $2 million.Bionomics Limited has filed a Follow-on Equity Offering in the amount of $2 million. Security Name: American Depositary Shares Security Type: Depositary Receipt (Common Stock) Transaction Features: At the Market Offering